Literature DB >> 17333081

Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting.

L Ostrosky-Zeichner1, C Sable, J Sobel, B D Alexander, G Donowitz, V Kan, C A Kauffman, D Kett, R A Larsen, V Morrison, M Nucci, P G Pappas, M E Bradley, S Major, L Zimmer, D Wallace, W E Dismukes, J H Rex.   

Abstract

The study presented here was performed in order to create a rule that identifies subjects at high risk for invasive candidiasis in the intensive care setting. Retrospective review and statistical modelling were carried out on 2,890 patients who stayed at least 4 days in nine hospitals in the USA and Brazil; the overall incidence of invasive candidiasis in this group was 3% (88 cases). The best performing rule was as follows: Any systemic antibiotic (days 1-3) OR presence of a central venous catheter (days 1-3) AND at least TWO of the following-total parenteral nutrition (days 1-3), any dialysis (days 1-3), any major surgery (days -7-0), pancreatitis (days -7-0), any use of steroids (days -7-3), or use of other immunosuppressive agents (days -7-0). The rate of invasive candidiasis among patients meeting the rule was 9.9%, capturing 34% of cases in the units, with the following performance: relative risk 4.36, sensitivity 0.34, specificity 0.90, positive predictive value 0.01, and negative predictive value 0.97. The rule may identify patients at high risk of invasive candidiasis.

Entities:  

Mesh:

Year:  2007        PMID: 17333081     DOI: 10.1007/s10096-007-0270-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.

Authors:  A M Rentz; M T Halpern; R Bowden
Journal:  Clin Infect Dis       Date:  1998-10       Impact factor: 9.079

2.  Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients.

Authors:  Renaud Piarroux; Frédéric Grenouillet; Patrick Balvay; Véronique Tran; Gilles Blasco; Laurence Millon; Annie Boillot
Journal:  Crit Care Med       Date:  2004-12       Impact factor: 7.598

3.  Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients.

Authors:  R K Pelz; C W Hendrix; S M Swoboda; M Diener-West; W G Merz; J Hammond; P A Lipsett
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

4.  Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey.

Authors:  H M Blumberg; W R Jarvis; J M Soucie; J E Edwards; J E Patterson; M A Pfaller; M S Rangel-Frausto; M G Rinaldi; L Saiman; R T Wiblin; R P Wenzel
Journal:  Clin Infect Dis       Date:  2001-06-20       Impact factor: 9.079

5.  Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials.

Authors:  Niki I Paphitou; Luis Ostrosky-Zeichner; John H Rex
Journal:  Med Mycol       Date:  2005-05       Impact factor: 4.076

6.  Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis?

Authors:  Hervé Dupont; Agnes Bourichon; Catherine Paugam-Burtz; Jean Mantz; Jean-Marie Desmonts
Journal:  Crit Care Med       Date:  2003-03       Impact factor: 7.598

7.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Authors:  S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

8.  Attributable mortality of nosocomial candidemia, revisited.

Authors:  Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal:  Clin Infect Dis       Date:  2003-10-08       Impact factor: 9.079

9.  Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination.

Authors:  Jorge Garbino; Daniel P Lew; Jacques-A Romand; Stéphane Hugonnet; Raymond Auckenthaler; Didier Pittet
Journal:  Intensive Care Med       Date:  2002-11-01       Impact factor: 17.440

10.  Candida colonization and subsequent infections in critically ill surgical patients.

Authors:  D Pittet; M Monod; P M Suter; E Frenk; R Auckenthaler
Journal:  Ann Surg       Date:  1994-12       Impact factor: 12.969

View more
  110 in total

Review 1.  Prophylaxis and treatment of invasive candidiasis in the intensive care setting.

Authors:  L Ostrosky-Zeichner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

2.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 3.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

4.  Failure to Validate a Multivariable Clinical Prediction Model to Identify Pediatric Intensive Care Unit Patients at High Risk for Candidemia.

Authors:  Brian T Fisher; Rachael K Ross; Emmanuel Roilides; Debra L Palazzi; Mark J Abzug; Jill A Hoffman; David M Berman; Priya A Prasad; A Russell Localio; William J Steinbach; Lambrini Vogiatzi; Ankhi Dutta; Theoklis E Zaoutis
Journal:  J Pediatric Infect Dis Soc       Date:  2015-04-29       Impact factor: 3.164

5.  A Risk Score for Fluconazole Failure among Patients with Candidemia.

Authors:  Luis Ostrosky-Zeichner; Rachel Harrington; Nkechi Azie; Hongbo Yang; Nanxin Li; Jing Zhao; Valerie Koo; Eric Q Wu
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 6.  [Invasive candidiasis in non-neutropenic adults : Guideline-based management in the intensive care unit].

Authors:  A Glöckner; O A Cornely
Journal:  Anaesthesist       Date:  2013-12       Impact factor: 1.041

7.  Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients.

Authors:  Laurence Senn; Philippe Eggimann; Riadh Ksontini; Andres Pascual; Nicolas Demartines; Jacques Bille; Thierry Calandra; Oscar Marchetti
Journal:  Intensive Care Med       Date:  2009-01-27       Impact factor: 17.440

Review 8.  Invasive candidiasis in pediatric intensive care units.

Authors:  Sunit Singhi; Akash Deep
Journal:  Indian J Pediatr       Date:  2009-11-12       Impact factor: 1.967

Review 9.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

10.  Liposomal amphotericin B displays rapid dose-dependent activity against Candida albicans biofilms.

Authors:  Gordon Ramage; Anto Jose; Leighann Sherry; David F Lappin; Brian Jones; Craig Williams
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.